Restore recycling capability of cells
Remove buildup of toxic protein
Recover patient wellbeing
Our Focus
KeifeRx is dedicated to providing new treatment options for neurodegenerative and immune diseases and bringing relief to the millions of people worldwide who are impacted by these debilitating, life-diminishing conditions.
Our Science
KeifeRx is building upon its extensive clinical experience in neurodegenerative diseases to advance a second generation of compounds that cross the blood-brain barrier, selectively target kinases to restore autophagy, and remove the build-up of toxic proteins to recover patient well-being.
These compounds have the potential to provide new therapeutic options for patients suffering from neurodegenerative and immune diseases.
Our Pipeline
KeifeRx is advancing second generation kinase inhibitors targeting neurodegenerative diseases including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease and dementia (PDD) and frontotemporal dementia. Additionally, KeifeRx is targeting inflammatory diseases, including mast cell activated syndromes (MCAS), Lyme disease, and Urticaria.
KeifeRx In The News
MAR 27, 2024
BUSINESSWIRE
KeifeRx Announces the Appointments of Dan Feehan and Alison Finger to Board of Directors
JAN 8, 2024
PR NEWSWIRE
KeifeRx Expands Exclusive Licensing Agreement with Georgetown University to Include Multiple Disease Indications for Portfolio of Novel Tyrosine Kinase Inhibitors